AliExpress Review – Never Buy Anything You Swallow or Inject

An Unusual Disclosure Before We Start

We are an affiliate. The affiliate programme was named. A reader deserves to know that the mechanism paying for this page is part of what a regulator asked the platform to fix, and that belongs at the top rather than in small print at the bottom.

So this review is written against our own commercial interest, and its central recommendation — do not buy anything you put in your body here — is the one most likely to cost us money. All details were checked on 8 August 2026. Nothing here is medical advice.

What the European Commission Found

This is not a customer-review aggregate or a blogger’s impression. It is a regulatory proceeding with dates.

Articles 34 and 35 are the substantive ones. They require very large online platforms to actively assess and mitigate the risks of illegal content and dangerous products on their services — not merely to remove things when told, but to run systems that find them. A preliminary finding of breach there is a finding about the platform’s architecture rather than about individual bad sellers.

The original proceedings also examined content moderation, complaint handling, advertising and recommender transparency, and the traceability of traders — that last one being the question of whether you can find out who actually sold you something.

Reporting has also described financial penalties in the hundreds of millions of euros in connection with this matter. We have read that in secondary coverage rather than a primary decision, so we flag the figure as reported rather than verified — the procedural facts above are the ones we are confident in.

The Rule This Site Will Not Qualify

We have spent this review series being careful about proportion — deflating overheated claims, noting when a complaint sample is too small, correcting ourselves when we found better information. This is the one recommendation we will not soften.

The reasoning is structural rather than moral:

• No supply chain verification. Across this series we have judged supplement brands on whether they publish batch certificates, name their laboratory, hold audited certifications and own their manufacturing. None of those questions can even be asked of an anonymous third-party seller.
• No regulator between you and the package. Whatever you think of FDA oversight of supplements — and we have written repeatedly that it is thinner than people assume — it is not nothing, and it does not apply here.
• Trader traceability was itself under investigation. If a product harms you, the ability to identify who sold it is the foundation of every remedy you might have.
• The Commission specifically named products affecting health. This is not our inference from general concerns; it is the category the binding commitments call out.

The asymmetry is what settles it. A counterfeit phone case is a wasted $4. A counterfeit capsule containing an undisclosed pharmaceutical, the wrong dose, or a heavy metal is a different category of outcome — and you would have no way of knowing until it had already happened.

Counterfeit GLP-1 Medication Is Real and Documented

This site is largely read by people taking or considering GLP-1 medication, so the general warning above has a specific and urgent form.

Two points of fairness, because overstating this would be its own failure. First, these seizures concerned the legitimate US supply chain rather than any particular website — the point is that counterfeit GLP-1 exists in commercial quantities, not that it came from one seller. Second, the FDA noted six adverse event reports associated with the lot, none of which appeared to be associated with the counterfeit product. We are not going to claim documented harm that the regulator did not.

The risk that is documented is enough on its own. An injectable whose needle sterility cannot be confirmed is a direct route past every barrier your body has — and unlike a pill you can decline to swallow, an injection is not reversible once given.

These drugs are expensive, and that is precisely the pressure that makes cheap sources attractive. We understand the arithmetic. If cost is the barrier, the routes worth pursuing are manufacturer patient assistance programmes, legitimate compounding through a licensed prescriber where lawful, and telehealth price comparison — all of which involve someone with a licence to lose. A marketplace listing does not.

The Price Advantage Was a Customs Loophole, and It Closed

If you have used AliExpress before and found it inexplicably cheap, here is the explanation — and why it no longer holds.

Section 321 of the Tariff Act of 1930, the de minimis exemption, allowed shipments valued under $800 to enter the United States duty-free. That is the reason orders historically arrived with nothing further to pay however cheap the item was.

This is the single most important thing to understand about the platform’s current value. Its advantage was substantially a regulatory arbitrage rather than a manufacturing or logistics one, and the arbitrage is gone. Any price comparison you remember from before May 2025 is obsolete, and any guide written before then is describing a world that no longer exists.

Choice Versus Independent Sellers: Know Which You Are Buying

This is the most immediately useful practical point on this page, and most buyers do not know it.

Same platform, two completely different purchases. One gives you a known total. The other can produce a customs bill weeks later that turns a bargain into a bad deal — and a charge arriving after the item does is exactly the kind of cost people fail to factor in when comparing prices.

Check which one you are in before you order, and treat an independent-seller listing as a price with an unknown addition rather than a price.

The Notorious Markets Question, Both Ways

The US Trade Representative publishes an annual Review of Notorious Markets for Counterfeiting and Piracy. AliExpress’s relationship with it has gone in both directions, and we report both.

• It has been listed. AliExpress was named in an earlier review, in 2022, alongside WeChat.
• It was not on the 2025 list — which is a genuine data point in the platform’s favour and we are not going to omit it.
• That omission was criticised. The Information Technology and Innovation Foundation ran its own investigation and recommended AliExpress, Temu and SHEIN all be listed, arguing the platform facilitates systemic trafficking in counterfeit goods.

Take the honest reading: not being on a list in a given year is weaker evidence than a live EU enforcement proceeding with preliminary findings of breach. The European record is the stronger and more recent signal, and it is the one we weight.

What It Is Genuinely Good For

A review that only prosecutes is not useful, and a blanket condemnation of AliExpress would be dishonest. Enormous numbers of people use it successfully.

It works well for:

• Cheap components, cables, adapters, hobby parts and consumables where a failure costs you a few dollars and nothing else.
• Things that genuinely are not available elsewhere — obsolete parts, niche sizes, specialist tooling.
• Purchases where you are willing to trade time for money. Shipping is slow; if that is acceptable, the platform is doing what it says.

The test we would apply: what is the worst outcome if this item is fake? If the answer is “I lost the money and some time”, the risk is priced in and the platform is a reasonable choice. If the answer involves your body, your home’s wiring, or a child, buy it somewhere accountable.

We would add anything load-bearing or electrical to the exclusion list on the same logic — chargers, batteries and safety equipment fail in ways that are not merely financial, which is why the Commission’s commitments name minors alongside health.

Buyer Protection and What It Cannot Fix

AliExpress operates a buyer protection and dispute system, and for the failure mode it is designed for — item not received, item not as described — it broadly functions. That is a real feature and worth stating.

This is the same distinction we drew reviewing a returns policy that required consumables be sent back unopened: a policy can be perfectly functional and still not cover the thing you actually need covering. Judge buyer protection on what it can restore, which is money.

How It Compares

Pros and Cons

How to Use It Sensibly

Apply the worst-case test to every item. If a fake costs you only money, proceed. If a fake could hurt you, buy elsewhere. That single rule handles almost every decision on the platform.

Never for supplements, medication, injectables or anything applied to broken skin. No exceptions, no price that justifies it, and no seller rating that substitutes for a supply chain.

We would extend that to electrical and load-bearing goods — chargers, batteries, safety equipment, anything for a child — because those also fail in ways a refund cannot address.

Prefer “Choice” listings so the tariff is settled at checkout rather than arriving later as a customs invoice, and re-run your price comparison from scratch — anything you remember about this platform’s pricing from before May 2025 predates the end of de minimis.

Limitations of This Review

We have not placed an order through AliExpress, tested its dispute process, or attempted to buy any product for examination. This is an assessment of the platform’s regulatory record and structure rather than a hands-on shopping review, and a platform this large plainly delivers satisfactory orders to enormous numbers of people every day — an assessment built on enforcement records will systematically under-represent that.

The reported financial penalty is our weakest-sourced figure and we have flagged it as reported rather than verified; the procedural dates and the Article 34 and 35 findings come from Commission material and are the parts we stand behind. Preliminary findings are not a final decision, commitments are not an admission of liability, and the process was ongoing at the time of writing with an action plan due 20 October 2026 — the position may have changed since.

The counterfeit Ozempic seizures did not concern this platform, and we have not claimed they did — they establish that counterfeit GLP-1 exists in commercial quantities, which is the basis for the caution rather than an allegation about any seller. We repeat that the FDA found the six adverse event reports for that lot did not appear associated with the counterfeit product. Tariff handling is as reported and customs treatment changes frequently; verify the current position before ordering. We did not read a Trustpilot record and publish no satisfaction score. None of this is medical, legal or tax advice.

Frequently Asked Questions

Verdict

The disclosure first, because it is the most unusual thing here. The European Commission’s binding DSA commitments cover AliExpress’s systems in relation to hidden links, its affiliate programme, and products potentially affecting health and minors. We are paid through that affiliate programme. We have put that at the top of the page rather than the bottom, and the review is written accordingly.

The regulatory record is the substance. Proceedings opened 14 March 2024; preliminary findings on 18 June 2025 identifying breaches of Articles 34 and 35 — the duties to actively assess and mitigate risks of illegal content and dangerous products; an action plan due 20 October 2026. That is a finding about how the platform is built, not about a few bad sellers. It was also on the USTR Notorious Markets List in an earlier review, though notably not on the 2025 list — a point in its favour that we include, and that a think tank publicly disputed.

The rule we will not qualify: never buy anything you swallow, inject, inhale or apply to broken skin. Every question we ask of a supplement brand in this series — who tested it, which laboratory, what did the batch certificate say, who is accountable — is unanswerable for an anonymous marketplace seller, and trader traceability was itself part of the investigation. For readers on GLP-1 medication this is not theoretical: the FDA seized counterfeit Ozempic in April and December 2025 after Novo Nordisk reported several hundred units in the supply chain, with counterfeit needles whose sterility could not be confirmed. In fairness, the FDA found the six adverse events for that lot did not appear linked to the counterfeit — the unconfirmable sterility is enough on its own.

And the value proposition has genuinely changed. The reason this platform was startlingly cheap was Section 321 — the de minimis exemption letting sub-$800 shipments in duty-free. That ended for China on 2 May 2025 and was suspended for all countries on 29 August 2025. Its advantage was substantially regulatory arbitrage, and the arbitrage is gone. Every price memory you have of this site is out of date.

Used within its limits it remains genuinely useful — unmatched range, real buyer protection for non-delivery, and things you cannot buy anywhere else. Prefer “Choice” listings so tariffs settle at checkout instead of arriving as a customs invoice weeks later.

Ask one question before every order: what happens if this is fake? If the answer is only money, go ahead. If the answer involves your body, buy it from someone with a licence to lose.